{"entity":{"id":"rc148","kind":"drug","name":"RC148","aka":["RC148 plus Platinum-Based Chemotherapy","RC148 for injection"],"tldr":"RC148 is an experimental investigational agent whose form is not stated in the registry from RemeGen in phase 3 trials for non-small-cell lung cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.","summary":"RC148 is an investigational agent whose form is not stated in the registry developed by RemeGen. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 20mg/kg, intravenous infusion, once every 2 weeks. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07416474 (RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)), in non-small-cell lung cancer and HR-positive / HER2-negative breast cancer. The largest, NCT07416474, plans to enrol 574 participants with primary completion expected 2027-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of RC148","url":"https://clinicaltrials.gov/search?intr=RC148"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["remegen"],"institutions":[],"pathways":[],"terms":[],"trials":["sqnsclc","nct07462143","nct06038396","nct06642545"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"bispecific antibody (PD-1 x VEGF, per the sponsor's pipeline page; form not stated in the registry record)","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rc148/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/"}],"trial":[{"id":"nct07462143","kind":"trial","name":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","route":"/trials/nct07462143/"},{"id":"nct06038396","kind":"trial","name":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","route":"/trials/nct06038396/"},{"id":"nct06642545","kind":"trial","name":"Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer","route":"/trials/nct06642545/"},{"id":"sqnsclc","kind":"trial","name":"RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)","route":"/trials/sqnsclc/"}]}}